In the past week, TRVI stock has gone down by -6.25%, with a monthly gain of 13.92% and a quarterly surge of 54.64%. The volatility ratio for the week is 9.91%, and the volatility levels for the last 30 days are 7.35% for Trevi Therapeutics Inc The simple moving average for the last 20 days is 5.84% for TRVI stock, with a simple moving average of 40.06% for the last 200 days.
Is It Worth Investing in Trevi Therapeutics Inc (NASDAQ: TRVI) Right Now?
The stock has a 36-month beta value of 0.91. Opinions on the stock are mixed, with 6 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TRVI is 52.84M, and at present, short sellers hold a 8.19% of that float. On February 28, 2025, the average trading volume of TRVI was 1.86M shares.
TRVI) stock’s latest price update
Trevi Therapeutics Inc (NASDAQ: TRVI)’s stock price has plunge by -0.22relation to previous closing price of 4.51. Nevertheless, the company has seen a -6.25% plunge in its stock price over the last five trading sessions. prnewswire.com reported 2025-02-27 that NEW HAVEN, Conn., Feb. 27, 2025 /PRNewswire/ — Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be attending the following investor conferences in March.
Analysts’ Opinion of TRVI
Many brokerage firms have already submitted their reports for TRVI stocks, with H.C. Wainwright repeating the rating for TRVI by listing it as a “Buy.” The predicted price for TRVI in the upcoming period, according to H.C. Wainwright is $7.50 based on the research report published on December 12, 2024 of the previous year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see TRVI reach a price target of $7, previously predicting the price at $6. The rating they have provided for TRVI stocks is “Outperform” according to the report published on September 09th, 2024.
Raymond James gave a rating of “Outperform” to TRVI, setting the target price at $9 in the report published on August 30th of the previous year.
TRVI Trading at 8.94% from the 50-Day Moving Average
After a stumble in the market that brought TRVI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -10.89% of loss for the given period.
Volatility was left at 7.35%, however, over the last 30 days, the volatility rate increased by 9.91%, as shares surge +16.58% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +25.00% upper at present.
During the last 5 trading sessions, TRVI fell by -6.25%, which changed the moving average for the period of 200-days by +54.11% in comparison to the 20-day moving average, which settled at $4.25. In addition, Trevi Therapeutics Inc saw 9.22% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TRVI starting from GOOD JENNIFER L, who sale 4,219 shares at the price of $3.03 back on Sep 06 ’24. After this action, GOOD JENNIFER L now owns 213,313 shares of Trevi Therapeutics Inc, valued at $12,784 using the latest closing price.
GOOD JENNIFER L, the President & CEO of Trevi Therapeutics Inc, sale 1,840 shares at $3.04 during a trade that took place back on Sep 09 ’24, which means that GOOD JENNIFER L is holding 213,313 shares at $5,587 based on the most recent closing price.
Stock Fundamentals for TRVI
Current profitability levels for the company are sitting at:
- -273.95 for the present operating margin
- 0.39 for the gross margin
The net margin for Trevi Therapeutics Inc stands at -251.8. The total capital return value is set at -0.81. Equity return is now at value -59.65, with -53.78 for asset returns.
Based on Trevi Therapeutics Inc (TRVI), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -31.5. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -6887.86.
Currently, EBITDA for the company is -33.8 million with net debt to EBITDA at 0.34. When we switch over and look at the enterprise to sales, we see a ratio of 2200.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.38.
Conclusion
To sum up, Trevi Therapeutics Inc (TRVI) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
